ÂÜÀòÂÒÂ×

Martin Babler is a seasoned executive with extensive experience in the biopharmaceutical industry. Currently serving as Chairman, President, and CEO of Alumis since September 2021, Babler also holds multiple board positions, including Board Member at Prelude Therapeutics, Sardona Therapeutics, Omega Alpha SPAC, and Neoleukin Therapeutics. Previously, Babler was the President and CEO of Principia Biopharma from April 2011 to October 2020 and led Talima Therapeutics in the same executive role from December 2007 to April 2011. Additional experience includes co-ownership of Paradigm Ranch Management LLC since February 2008 and a board member role at ZS Pharma, Inc. and MMA. Babler's leadership roles reflect a strong commitment to advancing therapeutic innovations and strategic growth in the biopharmaceutical sector.